Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxart Inc VXRT

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its programs include tablet vaccine candidates designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine candidate for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine candidate that protect against norovirus GI and norovirus GII, by targeting the norovirus GI.1 Norwalk strain and the norovirus GII.4 Sydney strain; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The Company is also developing therapeutic vaccines for cervical cancer.


NDAQ:VXRT - Post by User

<< Previous
Bullboard Posts
Next >>
User Avatar Image
(0)
•••
  • thevisionary2kX
Post by thevisionary2kon Feb 12, 2021 8:32am
272 Views
Post# 32550159

VXRT - Institutional Investors

VXRT - Institutional Investors

Let’s put into perspective the VXRT-State Street, BlackRock and Vanguard investments - three (3) of largest asset management and investment firms in the world with $18 Trillion in Assets.

 

State Street:

  • Total Assets: $3.2 Trillion
  • VXRT Shares: 9.5 Million
  • VXRT Share % Change: 33,072%
  • Current VXRT Market Value: $81.8 Million

 

BlackRock

  • Total Assets: $8.7 Trillion
  • VXRT Shares: 4.9 Million
  • VXRT Share % Change: 645%
  • Current VXRT Market Value: $42.8 Million

 

Vanguard Group

  • Total Assets: $6.2 Trillion
  • VXRT Shares: 5.0 Million
  • VXRT Share % Change: 27%
  • Current VXRT Market Value: $43.3 Million

 

Combined, the Current VXRT Market Value is $167.9 Million, equating to 20.4 million shares owned, while their VXRT share percentage change ranges from 27% - 33,072%.

 

State Street, BlackRock and Vanguard would not have increased its investments in VXRT without performing proper due diligence.

<< Previous
Bullboard Posts
Next >>